MARKET

PLX

PLX

PROTALIX BIOTHER
AMEX

Real-time Quotes | Nasdaq Last Sale

1.380
-0.020
-1.43%
Opening 15:52 09/28 EDT
OPEN
1.390
PREV CLOSE
1.400
HIGH
1.415
LOW
1.360
VOLUME
383.48K
TURNOVER
--
52 WEEK HIGH
7.02
52 WEEK LOW
1.280
MARKET CAP
62.87M
P/E (TTM)
-2.7187
1D
5D
1M
3M
1Y
5Y
Protalix BioTherapeutics Announces Closing of Private Note Exchange
CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ...
PR Newswire - PRF · 08/26 10:50
PLX: Debt Maturities Resolved
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT
Benzinga · 08/22 09:21
Protalix BioTherapeutics Q2 EPS $(0.25) Down From $(0.13) YoY
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.25) per share. This is a 92.31 percent decrease over losses of $(0.13) per share from the same period last year.
Benzinga · 08/16 10:51
Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein ex...
PR Newswire · 08/16 10:50
Protalix BioTherapeutics Announces Private Note Exchange
CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...
PR Newswire - PRF · 08/13 10:50
Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein ex...
PR Newswire · 08/09 11:15
Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application
Benzinga · 08/02 12:03
Protalix Bio submits Type A meeting request to FDA for PRX-102 in Fabry disease
Protalix BioTherapeutics (NYSE:PLX) perks up 2% premarket after submitting Type A Meeting request to the FDA to discuss the Complete Response Letter (CRL) dated April 27, 2021 regarding the Biologics License Application for
Seekingalpha · 08/02 11:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLX. Analyze the recent business situations of PROTALIX BIOTHER through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PLX stock price target is 9.75 with a high estimate of 12.50 and a low estimate of 7.00.
High12.50
Average9.75
Low7.00
Current 1.370
EPS
Actual
Estimate
-0.20-0.14-0.09-0.04
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 32
Institutional Holdings: 12.41M
% Owned: 27.25%
Shares Outstanding: 45.56M
TypeInstitutionsShares
Increased
6
1.51M
New
7
1.67M
Decreased
3
89.21K
Sold Out
9
231.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.65%
Pharmaceuticals & Medical Research
-1.54%
Key Executives
Chairman/Director
Zeev Bronfeld
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President
Eyal Rubin
Senior Vice President
Einat Almon
Senior Vice President
Yaron Naos
Vice President - Research & Development
Yael Hayon
Director
Pol Boudes
Director
Gwen Melincoff
Independent Director
Amos Bar-Shalev
Independent Director
David Granot
Independent Director
Aharon Schwartz
No Data
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.